These data strongly support the hypothesis that pirfenidone could improve the progression of cardiac hypertrophy and remodeling induced by Ang II ... Role of the renin–angiotensin–aldosterone ...

Angiotensin II binding to AT 1 R can also induce cardiac dysfunction including hypertrophy, arrhythmia, and ventricle function failure. Excessive angiotensin II can also lead to large inflammatory ...

Role of the RAAS in the Pathophysiology of Heart Failure ACE inhibitors have no effect on angiotensin II formed by alternate pathways. In contrast, ARBs would be expected to inhibit the biologic ...

angiotensin-receptor blockers (ARBs), or spironolactone. Cardiac MRI studies with the administration of gadolinium were performed in 28 subjects with overt hypertrophic cardiomyopathy and 32 ...

For example, angiotensin-converting ... including myocardial infarction, cardiomyopathy, hypertension, and valvular heart disease; its hallmarks include hypertrophy, loss of myocytes, and ...

Angiotensin II receptor blockers (ARBs ... There’s some evidence that people on ACE inhibitors are less prone to myocardial infarction (MI) and fatal heart and cardiovascular events than ...

Several ongoing large clinical trials involving thousands of patients with congestive heart failure, post-myocardial infarction, left ventricular hypertrophy, and diabetic nephropathy will be ...

Angiotensin-converting enzyme inhibitors ... such as left ventricular hypertrophy, microalbuminuria, proteinuria, myocardial infarction, stroke, heart failure, atrial fibrillation, renal disorder ...

New treatments for cardiac ... hypertrophy, Feneley said, noting that hypertrophy is a response to stimuli, and there have been two different suspected pathways in the literature, one of which was ...

In the aorta, angiotensin II promotes hypertrophy of vascular smooth muscle cells through angiotensin type 1 receptor (AT1R), resulting in hypertension by increasing arterial wall thickness and ...

Heart failure is the terminal stage of various cardiovascular diseases, usually characterized by pathological myocardial hypertrophy. So far, the pathogenesis of heart failure is not fully understood.